摘要
Background: The World Health Organization (WHO) has set a goal to eradicate or at least significantly reduce the prevalence the human immunodeficiency virus (HIV), hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) by 2030. The main objective was to provide an evolving overview of the prevalence of HIV, HBV and HCV infection between 2003 and 2022 in Burkina Faso. Methods: It was a retrospective cross-sectional study based on data from 2003 to 2022. The data were collected using information available in the databases of the HOSCO and CERBA laboratories and included all individuals who underwent HIV and/or HBV and/or HCV testing. Data analysis was performed using SPSS version 20.0, EpiInfo 7, and R version 4.1.0. Results were considered statistically significant if p Results: The study recorded 7432 samples and the mean age of the subjects was 27.98 ± 8.50 years. During this period, the respective prevalence of HIV, HBV, and HCV were 4.66% (346/7432), 8.77% (582/6636) and 5.54% (322/5816). However, from 2003 to 2022, there was a significant decrease (P y=−1.75x+12.59;y=−0.24x+10.01and y=−0.11x+6.02, with “y” corresponding to prevalence and “x” to the years. Conclusion: Burkina Faso needs to rigorously apply prevention and control strategies recommended by the WHO by 2030.
Background: The World Health Organization (WHO) has set a goal to eradicate or at least significantly reduce the prevalence the human immunodeficiency virus (HIV), hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) by 2030. The main objective was to provide an evolving overview of the prevalence of HIV, HBV and HCV infection between 2003 and 2022 in Burkina Faso. Methods: It was a retrospective cross-sectional study based on data from 2003 to 2022. The data were collected using information available in the databases of the HOSCO and CERBA laboratories and included all individuals who underwent HIV and/or HBV and/or HCV testing. Data analysis was performed using SPSS version 20.0, EpiInfo 7, and R version 4.1.0. Results were considered statistically significant if p Results: The study recorded 7432 samples and the mean age of the subjects was 27.98 ± 8.50 years. During this period, the respective prevalence of HIV, HBV, and HCV were 4.66% (346/7432), 8.77% (582/6636) and 5.54% (322/5816). However, from 2003 to 2022, there was a significant decrease (P y=−1.75x+12.59;y=−0.24x+10.01and y=−0.11x+6.02, with “y” corresponding to prevalence and “x” to the years. Conclusion: Burkina Faso needs to rigorously apply prevention and control strategies recommended by the WHO by 2030.
作者
Abdou Azaque Zouré
Christelle Nadembega
Djénéba Ouermi
Abdoul Karim Ouattara
Lassina Traoré
Adama Tiemtoré
Olivier Sawadogo
Théodora M. Zohoncon
Florencia W. Djigma
Jacques Simpore
Cerba-Labiogene Group
Abdou Azaque Zouré;Christelle Nadembega;Djénéba Ouermi;Abdoul Karim Ouattara;Lassina Traoré;Adama Tiemtoré;Olivier Sawadogo;Théodora M. Zohoncon;Florencia W. Djigma;Jacques Simpore;Cerba-Labiogene Group(Centre de Recherche Biomolculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso;Laboratoire de Biologie Molculaire et de Gntique (LABIOGENE), Universit Joseph KI-ZERBO, Ouagadougou, Burkina Faso;Institute for Research in Health Sciences (IRSS/CNRST), Ouaga, Burkina Faso;Department of Biomedical, Hpital Saint Camille de Ouagadougou (HOSCO), Ouagadougou, Burkina Faso;Department of Biology, Universit Norbert Zongo/Centre Universitaire de Manga, Koudougou, Burkina Faso;Department of Mathematic, Universit de Ouahigouya, Ouahigouya, Burkina Faso;Faculty of Medicine, University Saint Thomas dAquin (USTA), Ouagadougou, Burkina Faso)
